The GIRAFE phase II trial on MVCT-based “volumes of the day” and “dose of the day” addresses when and how to implement adaptive radiotherapy for locally advanced head and neck cancer
During exclusive curative radiotherapy for head and neck tumors, the patient’s organs at risk (OAR) and target volumes frequently change size and shape, leading to a risk of higher toxicity and lower control than expected on planned dosimetry. Adaptive radiotherapy is often necessary but 1) tools ar...
Main Authors: | , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-05-01
|
Series: | Clinical and Translational Radiation Oncology |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2405630818301265 |
id |
doaj-853faf3f1722433493b31a0134b24f2e |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Vincent Esteyrie Baptiste Gleyzolle Amélie Lusque Pierre Graff Anouchka Modesto Michel Rives Michel Lapeyre Jacques Desrousseaux Eliane Graulières Gregory Hangard François-Xavier Arnaud Regis Ferrand Jean-Pierre Delord Muriel Poublanc Muriel Mounier Thomas Filleron Anne Laprie |
spellingShingle |
Vincent Esteyrie Baptiste Gleyzolle Amélie Lusque Pierre Graff Anouchka Modesto Michel Rives Michel Lapeyre Jacques Desrousseaux Eliane Graulières Gregory Hangard François-Xavier Arnaud Regis Ferrand Jean-Pierre Delord Muriel Poublanc Muriel Mounier Thomas Filleron Anne Laprie The GIRAFE phase II trial on MVCT-based “volumes of the day” and “dose of the day” addresses when and how to implement adaptive radiotherapy for locally advanced head and neck cancer Clinical and Translational Radiation Oncology |
author_facet |
Vincent Esteyrie Baptiste Gleyzolle Amélie Lusque Pierre Graff Anouchka Modesto Michel Rives Michel Lapeyre Jacques Desrousseaux Eliane Graulières Gregory Hangard François-Xavier Arnaud Regis Ferrand Jean-Pierre Delord Muriel Poublanc Muriel Mounier Thomas Filleron Anne Laprie |
author_sort |
Vincent Esteyrie |
title |
The GIRAFE phase II trial on MVCT-based “volumes of the day” and “dose of the day” addresses when and how to implement adaptive radiotherapy for locally advanced head and neck cancer |
title_short |
The GIRAFE phase II trial on MVCT-based “volumes of the day” and “dose of the day” addresses when and how to implement adaptive radiotherapy for locally advanced head and neck cancer |
title_full |
The GIRAFE phase II trial on MVCT-based “volumes of the day” and “dose of the day” addresses when and how to implement adaptive radiotherapy for locally advanced head and neck cancer |
title_fullStr |
The GIRAFE phase II trial on MVCT-based “volumes of the day” and “dose of the day” addresses when and how to implement adaptive radiotherapy for locally advanced head and neck cancer |
title_full_unstemmed |
The GIRAFE phase II trial on MVCT-based “volumes of the day” and “dose of the day” addresses when and how to implement adaptive radiotherapy for locally advanced head and neck cancer |
title_sort |
girafe phase ii trial on mvct-based “volumes of the day” and “dose of the day” addresses when and how to implement adaptive radiotherapy for locally advanced head and neck cancer |
publisher |
Elsevier |
series |
Clinical and Translational Radiation Oncology |
issn |
2405-6308 |
publishDate |
2019-05-01 |
description |
During exclusive curative radiotherapy for head and neck tumors, the patient’s organs at risk (OAR) and target volumes frequently change size and shape, leading to a risk of higher toxicity and lower control than expected on planned dosimetry. Adaptive radiotherapy is often necessary but 1) tools are needed to define the optimal time for replanning, and 2) the subsequent workflow is time-consuming.We designed a prospective study to evaluate 1) the validity of automatically deformed contours on the daily MVCT, in order to safely use the “dose-of the day” tool to check daily if replanning is necessary; 2) the automatically deformed contours on the replanning CT and the time gained in the replanning workflow.Forty-eight patients with T3-T4 and/or involved node >2 cm head and neck squamous cell carcinomas, planned for curative radiotherapy without surgery, will be enrolled. They will undergo treatment with helical IMRT including daily repositioning MVCTs. The contours proposed will be compared weekly on intermediate planning CTs (iCTs) on weeks 3, 4, 5 and 6. On these iCTs both manual recontouring and automated deformable registration of the initial contours will be compared with the contours automatically defined on the MVCT. The primary objective is to evaluate the Dice similarity coefficient (DSC) of the volumes of each parotid gland. The secondary objectives will evaluate, for target volumes and all OARs: the DSC, the mean distance to agreement, and the average surface-to-surface distance. Time between the automatic and the manual recontouring workflows will be compared. |
url |
http://www.sciencedirect.com/science/article/pii/S2405630818301265 |
work_keys_str_mv |
AT vincentesteyrie thegirafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer AT baptistegleyzolle thegirafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer AT amelielusque thegirafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer AT pierregraff thegirafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer AT anouchkamodesto thegirafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer AT michelrives thegirafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer AT michellapeyre thegirafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer AT jacquesdesrousseaux thegirafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer AT elianegraulieres thegirafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer AT gregoryhangard thegirafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer AT francoisxavierarnaud thegirafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer AT regisferrand thegirafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer AT jeanpierredelord thegirafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer AT murielpoublanc thegirafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer AT murielmounier thegirafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer AT thomasfilleron thegirafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer AT annelaprie thegirafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer AT vincentesteyrie girafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer AT baptistegleyzolle girafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer AT amelielusque girafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer AT pierregraff girafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer AT anouchkamodesto girafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer AT michelrives girafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer AT michellapeyre girafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer AT jacquesdesrousseaux girafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer AT elianegraulieres girafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer AT gregoryhangard girafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer AT francoisxavierarnaud girafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer AT regisferrand girafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer AT jeanpierredelord girafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer AT murielpoublanc girafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer AT murielmounier girafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer AT thomasfilleron girafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer AT annelaprie girafephaseiitrialonmvctbasedvolumesofthedayanddoseofthedayaddresseswhenandhowtoimplementadaptiveradiotherapyforlocallyadvancedheadandneckcancer |
_version_ |
1721406484098580480 |
spelling |
doaj-853faf3f1722433493b31a0134b24f2e2021-06-02T08:25:47ZengElsevierClinical and Translational Radiation Oncology2405-63082019-05-01163439The GIRAFE phase II trial on MVCT-based “volumes of the day” and “dose of the day” addresses when and how to implement adaptive radiotherapy for locally advanced head and neck cancerVincent Esteyrie0Baptiste Gleyzolle1Amélie Lusque2Pierre Graff3Anouchka Modesto4Michel Rives5Michel Lapeyre6Jacques Desrousseaux7Eliane Graulières8Gregory Hangard9François-Xavier Arnaud10Regis Ferrand11Jean-Pierre Delord12Muriel Poublanc13Muriel Mounier14Thomas Filleron15Anne Laprie16Radiation Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Oncopole, Toulouse, FranceRadiation Oncology, Centre Jean Perrin, Clermont-Ferrand, FranceBiostatistics Unit, Institut Claudius Regaud-, Institut Universitaire du Cancer de Toulouse – Oncopole Toulouse, FranceRadiation Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Oncopole, Toulouse, FranceRadiation Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Oncopole, Toulouse, FranceRadiation Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Oncopole, Toulouse, FranceRadiation Oncology, Centre Jean Perrin, Clermont-Ferrand, FranceRadiation Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Oncopole, Toulouse, FranceEngineering and Medical Physics, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse – Oncopole. Toulouse, FranceEngineering and Medical Physics, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse – Oncopole. Toulouse, FranceEngineering and Medical Physics, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse – Oncopole. Toulouse, FranceEngineering and Medical Physics, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse – Oncopole. Toulouse, FranceClinical Trials Office , Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse – Oncopole. Toulouse, FranceClinical Trials Office , Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse – Oncopole. Toulouse, FranceClinical Trials Office , Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse – Oncopole. Toulouse, FranceBiostatistics Unit, Institut Claudius Regaud-, Institut Universitaire du Cancer de Toulouse – Oncopole Toulouse, FranceRadiation Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Oncopole, Toulouse, France; Corresponding author.During exclusive curative radiotherapy for head and neck tumors, the patient’s organs at risk (OAR) and target volumes frequently change size and shape, leading to a risk of higher toxicity and lower control than expected on planned dosimetry. Adaptive radiotherapy is often necessary but 1) tools are needed to define the optimal time for replanning, and 2) the subsequent workflow is time-consuming.We designed a prospective study to evaluate 1) the validity of automatically deformed contours on the daily MVCT, in order to safely use the “dose-of the day” tool to check daily if replanning is necessary; 2) the automatically deformed contours on the replanning CT and the time gained in the replanning workflow.Forty-eight patients with T3-T4 and/or involved node >2 cm head and neck squamous cell carcinomas, planned for curative radiotherapy without surgery, will be enrolled. They will undergo treatment with helical IMRT including daily repositioning MVCTs. The contours proposed will be compared weekly on intermediate planning CTs (iCTs) on weeks 3, 4, 5 and 6. On these iCTs both manual recontouring and automated deformable registration of the initial contours will be compared with the contours automatically defined on the MVCT. The primary objective is to evaluate the Dice similarity coefficient (DSC) of the volumes of each parotid gland. The secondary objectives will evaluate, for target volumes and all OARs: the DSC, the mean distance to agreement, and the average surface-to-surface distance. Time between the automatic and the manual recontouring workflows will be compared.http://www.sciencedirect.com/science/article/pii/S2405630818301265 |